| 1. |
- Georgiadis, Stylianos, et al.
(författare)
-
An approach for eliciting requirements from digital sources in organisations using the Scrum method
- 2024
-
Ingår i: Companion Proceedings of the 16th IFIP WG 8.1 Working Conference on the Practice of Enterprise Modeling and the 13th Enterprise Design and Engineering Working Conference, November 28 – December 1, 2023, Vienna, Austria.
-
Konferensbidrag (refereegranskat)abstract
- The business world is nowadays characterized by complexity due to rapidly evolving market and customer requirements. As a consequence, software providers are facing the challenge of delivering products with higher pace and innovation. The agile methodology has a big impact on how software systems are developed - it should facilitate business value in short iterations. Requirements are the base of all software systems, and consequently, Requirements Engineering (RE) plays one of the most important roles in system development. Traditional elicitation techniques relying on stakeholders’ requests do not cover the increasing demands for considering unintended data from organisations' related digital sources, internal (transaction logs, sensors) or external (e.g., microblogs), amplifying thus the need for the elicitation of data-driven requirements. This study proposes a process that combines data-driven and traditional RE approaches for Agile software development, and specifically for the Scrum method. The process intends to assist Agile professionals to elicit requirements from digital sources in combination with intended data derived from the stakeholders without impacting the main Agile practices. The motivation for the research origins from the case studies carried in few companies having the challenge to include data-driven requirements into their Agile approaches. The usage of the proposal is illustrated on an enterprise software case, while several Scrum professionals were interviewed to evaluate its correctness and importance.
|
|
| 2. |
- Ørnbjerg, Lykke M., et al.
(författare)
-
Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care
- 2024
-
Ingår i: Journal of Rheumatology. - 0315-162X. ; 51:4, s. 378-389
-
Tidskriftsartikel (refereegranskat)abstract
- Objective. To evaluate patient-reported outcomes (PROs) after initiation of tumor necrosis factor inhibitor (TNFi) treatment in European real-world patients with psoriatic arthritis (PsA). Further, to investigate PRO remission rates across treatment courses, registries, disease duration, sex, and age at disease onset. Methods. Visual analog scale or numerical rating scale scores for pain, fatigue, patient global assessment (PtGA), and the Health Assessment Questionnaire–Disability Index (HAQ-DI) from 12,262 patients with PsA initiating a TNFi in 13 registries were pooled. PRO remission rates (pain ≤ 1, fatigue ≤ 2, PtGA ≤ 2, and HAQ-DI ≤ 0.5) were calculated for patients still on the treatment. Results. For the first TNFi, median pain score was reduced by approximately 50%, from 6 to 3, 3, and 2; as were fatigue scores, from 6 to 4, 4, and 3; PtGA scores, from 6 to 3, 3, and 2; and HAQ-DI scores, from 0.9 to 0.5, 0.5, and 0.4 at baseline, 6, 12, and 24 months, respectively. Six-month Lund Efficacy Index (LUNDEX)–adjusted remission rates for pain, fatigue, PtGA, and HAQ-DI scores were 24%, 31%, 36%, and 43% (first TNFi); 14%, 19%, 23%, and 29% (second TNFi); and 9%, 14%, 17%, and 20% (third TNFi), respectively. For biologic-naïve patients with disease duration < 5 years, 6-month LUNDEX-adjusted remission rates for pain, fatigue, PtGA, and HAQ-DI scores were 22%, 28%, 33%, and 42%, respectively. Corresponding rates for patients with disease duration > 10 years were 27%, 32%, 41%, and 43%, respectively. Remission rates were 33%, 40%, 45%, and 56% for men and 17%, 23%, 24%, and 32% for women, respectively. For patients aged < 45 years at diagnosis, 6-month LUNDEX-adjusted remission rate for pain was 29% vs 18% for patients ≥ 45 years. Conclusion. In 12,262 biologic-naïve patients with PsA, 6 months of treatment with a TNFi reduced pain by approximately 50%. Marked differences in PRO remission rates across treatment courses, registries, disease duration, sex, and age at onset of disease were observed, emphasizing the potential influence of factors other than disease activity on PROs.
|
|
